Figure 1

Experimental design for pathogen derived, urinary peptide identification and authentication. Experimental analysis and bioinformatics pipeline was applied to a first set of n = 110 individuals, n = 10 acute Lyme borreliosis patients according to CDC criteria and n = 100 controls, comprising healthy and diseased non-Lyme participants. Parameters for peptide identification and authentications were established in this first phase. The method was verified in an independent set of n = 298 participants, including n = 148 non acute patients suspected of tick-borne illness and n = 150 healthy and diseased controls. Urinary peptides were validated by means of orthogonal methods including western blot analysis, parallel reaction monitoring, and a Babesia animal model. PTLDS post treatment Lyme disease syndrome.